Recce Pharmaceuticals will trial its anti-infective agents RECCE 327 and RECCE 529 against SARS- CoV-2.
The company has teamed with North Carolina’s Path BioAnalytics to trial its broad-spectrum synthetic antibiotics which the company is commercialising to defeat resistant superbugs,
Researchers at PBA will evaluate the company’s drug candidates in an ‘ex vivo respiratory organoid model system’.
The study will be conducted in the Biosafety Level 3 containment laboratories of a leading US research university, where the infection of the organoids with SARS-CoV-2 will take place.
The purpose of the study is to evaluate both compound therapies for the prevention and/or mitigation of SARS-CoV-2 with preliminary data anticipated by September 2020.
RECCE 327 is a broad-spectrum synthetic antibiotic formulated using synthetic polymer technology to treat blood infections and sepsis.
RECCE 529 is a new synthetic polymer formulation, built upon the Company’s anti-infective expertise.
Recce Pharmaceuticals Non-Executive Chairman John Prendergast: “The current pandemic underscores the need for more effective treatment approaches to prevent infectious diseases.
“Over the past few months Recce has received a number of expressions of interest from several universities and research organisations to collaborate on the development of potential new therapies.”
Recce said the trial was not an indication that the compounds are safe or effective for use in treatment of SARS-CoV-2.
Picture: Recce Pharmaceticals
Subscribe to our free @AuManufacturing newsletter here.